SCHEMBL2575438

SCHEMBL2575438

CCCCCCCC/C=C\CCCCCCC(C)OCC[O]

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.44
TRPV1 Q8NER1 1/20 0.44
ALDH1A1 P00352 1/20 0.41
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
LPAR3 Q9UBY5 1/20 0.40
FFAR1 O14842 1/20 0.40
FFAR4 Q5NUL3 1/20 0.40
GMNN O75496 1/20 0.40
USP2 O75604 1/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
CYP2C9 P11712 1/20 0.40
ALOX15 P16050 1/20 0.40
APEX1 P27695 1/20 0.40
CYP2C19 P33261 1/20 0.40
RECQL P46063 1/20 0.40
BLM P54132 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoric Acid SCHEMBL4163600 0.93 LPAR3 (0.49) LPAR3
SCHEMBL3804996 0.89 FAAH (0.42) FAAHALDH1A1CNR1CNR2
SCHEMBL4602462 0.89 FAAH (0.42) FAAHALDH1A1CNR1CNR2
SCHEMBL7139631 0.89 FAAH (0.42) FAAHALDH1A1CNR1CNR2
SCHEMBL5538149 0.89 FAAH (0.42) FAAHALDH1A1CNR1CNR2
SCHEMBL1142548 0.88 ALDH1A1 (0.47) FAAHTRPV1ALDH1A1CNR1CNR2
SCHEMBL1142899 0.88 FAAH (0.44) FAAHTRPV1ALDH1A1CNR1CNR2
SCHEMBL1142291 0.88 FAAH (0.44) FAAHTRPV1ALDH1A1CNR1CNR2
SCHEMBL1142329 0.88 ALDH1A1 (0.47) FAAHTRPV1ALDH1A1CNR1CNR2
SCHEMBL4018632 0.88 ALDH1A1 (0.51) FAAHTRPV1ALDH1A1CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3073263-B1 DEVICE, COMPOSITION AND METHOD FOR TISSUE-BASED DIAGNOSIS UNIV CALIFORNIA (US) 2020-04-29 EP claimed
CN-104655828-B System, the method and apparatus of diagnosis based on tissue 加州大学评议会 2018-04-27 CN claimed
US-9848853-B2 System, method and devices for tissue-based diagnosis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-12-26 US claimed
EP-3073263-A1 SYSTEM, METHOD AND DEVICE FOR TISSUE-BASED DIAGNOSIS The Regents of the University of California (US) 2016-09-28 EP claimed
US-20160235392-A1 SYSTEM, METHOD AND DEVICES FOR TISSUE-BASED DIAGNOSIS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-08-18 US claimed
US-9328324-B2 System, method and devices for tissue-based diagnosis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-05-03 US claimed
US-20150344834-A1 System, Method and Devices for Tissue-Based Diagnosis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2015-12-03 US claimed
CN-104655828-A SYSTEM, METHOD AND DEVICE FOR TISSUE-BASED DIAGNOSIS UNIV CALIFORNIA 2015-05-27 CN claimed
US-8945482-B2 System, method and device for tissue-based diagnosis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-02-03 US claimed
EP-1163902-B1 Transdermal preparation containing hydrophilic or salt-form drug PACIFIC CORP (KR) 2007-01-17 EP claimed
EP-0948362-B1 ESSENTIAL OIL SOLID COMPOSITIONS MONOPACE PTY LTD (AU) 2006-02-01 EP claimed
EP-1100465-B1 MEDICINAL AEROSOL FORMULATIONS JAGO RES AG (CH) 2004-11-24 EP claimed
US-11607407-B2 Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use RELMADA THERAPEUTICS, INC. (US) 2023-03-21 US disclosed
CN-107115326-B Skin pharmaceutical composition of 1-methyl-N- (2, 6-xylyl) -2-piperidine formamide and using method thereof 雷尔玛达治疗股份有限公司 2021-01-22 CN disclosed
EP-2557924-B1 DERMAL PHARMACEUTICAL COMPOSITIONS OF 1-METHYL-2',6'-PIPECOLOXYLIDIDE AND METHOD OF USE RELMADA THERAPEUTICS INC (US) 2019-06-12 EP disclosed
US-9848853-B2 System, method and devices for tissue-based diagnosis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-12-26 US disclosed
US-20040077501-A1 Agrochemical formulation aid composition and uses thereof ADJUVANTS PLUS INC. (CA) 2004-04-22 US disclosed
EP-1330159-A1 AGROCHEMICAL FORMULATION AID COMPOSITION AND USES THEREOF Adjuvants Plus Inc. (CA) 2003-07-30 EP disclosed
WO-2002034047-A1 AGROCHEMICAL FORMULATION AID COMPOSITION AND USES THEREOF ADJUVANTS PLUS INC. (CA) 2002-05-02 WO disclosed
US-5171475-A Progenitor solution of solvent, emulsifier, surfactant having specific polarity and refractive index; water PENETONE CORPORATION (US) 1992-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11607407-B2 Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use PIP4K2C, PIP5K1C, PIP4K2A FAAH 4077/4885TRPV1 1716/4885ALDH1A1 1497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.